Share
Announcing the latest report by GIA for Anxiety Disorder Market states that the global market is about to reach $5.9 billion for anxiety disorder by the year 2017. Continuous increase in stress level, growing aging population, financial crises, unmet needs, increase in demands and the rise of novel therapeutics are the main reasons for rise in the market growth.
Twenty first century is known as the ‘Global Epidemics’ period where stress is considered to be one of the most significant health issues. The only thing that helps during stress is anxiety. It helps us to deal with all kind of stress levels in office, work harder during exams, preparing an important presentation for client or even the stress related to day to day life. Now days, anxiety is affecting almost all age group people disturbing their mental health condition and irritating at times.
The other important reason for anxiety is global financial crisis; leading to ups and downs in the market has made his way for rising stress level to maximum level. The fear of loosing any job and even not having it makes a person burdened up with stress. The aging global population is being one of the major factors for tremendous increase in sales of central nervous system drugs. Anxiety disorders are many of its kind including Social Anxiety Disorder, Post – Traumatic Stress Disorder, Generalized Anxiety Disorder, and Obsessive –Compulsive Disorder.
Anxiety therapy targets and eradicates few factors causing disorder and reduces its reoccurrence, thus helping in sustaining and developing normal health of a person. The agents do use Prozac (Fluxotine), Paxil(Paroxetine), Zoloft (Sertraline), and Lexapro (Escitalopram). New antidepressant including Remeron (Mirtazapine)of GABA; and MAOIs including Lyrica (Pregabalin) or Neurontin (Gabapentin), Parnate (Tranylcypromine) or Nardil (Phenelzine). A typical anti-psychotics gas Quetiappine, TCAs has Imipramine and Piperazines with hydroxyzine are consumed for the treatment of anxiety. Along with the treatment it also brings various complications and harmful side effect.
In spite of being the foundation for pharmacological treatment affecting the anxiety disorder, the rate of response from serotonergic-based treatment is more even below than the healthy level. There are many people suffering from the anxiety disorders, around one –third of patients anguishing from psychiatric conditions, still it do not react to the drugs that are available in market. The market demands an ever rising supply of these medicines at a very fast rate as compared to the other drugs available ion the market. The conventional modes are undertaken by the companies like adjustment of nor- adrenaline and serotonin level in the brain and on the new mechanisms too for treating anxiety.
The Corticotrophin Releasing Factor (CRF) antagonists and Neurokinin (NK) receptor antagonists are driving the major interest from the main market participants. NK receptors antagonist is the vital drug that is expecting to be promising in coming days. Market might demand the huge supply of NK, as there is growth in potential patients of anxiety. The transformation of market is expected in coming days to modify the potential landscape of anxiety disorder drugs market. Taking consideration into higher co-morbidity between depression and anxiety, the manufacturer of the antidepressant are focusing more on products target patient potential.
The new market research report states that the US stands first for the largest regional market for anxiety disorder therapeutics worldwide. The study reveals, US gained US$42 million per annum only for the anxiety disorders. This turns around one third of the total cost for mental illness. Brain disorders along with the depression are being the most common health problem covering 27% of the European Population. The fastest growth of the anxiety disorders is seen in Asia – Pacific, calculating the annual growth of 5.0% during 2009-2017.
Major companies profiled in the report include Watson Laboratories, AstraZeneca Plc., Sanofi-Aventis, Boehringer Ingelheim GmbH, Pfizer Inc., Bristol-Myers Squibb Company, Valeant Pharmaceuticals, Eli Lilly and Company, Ratiopharm, F. Hoffmann-La Roche Ltd., Neurocrine Biosciences, Inc., Forest Laboratories, Inc., H. Lundbeck A/S, Mylan Inc., GlaxoSmithKline Plc etc.
The above report by Global Industry Analyst Inc. brings an intact report of anxiety disorders therapeutics markets, key growth drivers, overview of pipeline drugs, recent industry activity, current market trends, leading drugs in the market, recent product approvals/launches, profiles of major/niche global as well as regional market participants.
The above report is concluded annually for anxiety disorders therapeutics market (2009-2017) for the geographic markets - Asia-Pacific, US, Europe, and Rest of World.
| < Prev |
|---|
